Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D in Pregnancy: Maternal and Fetal Outcomes: Study Summary

Previous related pageVitamin D in Pregnancy: Maternal and Fetal Outcomes: Full Evidence ReviewNext related pageVitamin D in Pregnancy: Maternal and Fetal Outcomes: Full Evidence Review
Study at a glance

What was the question?

Does vitamin D status or supplementation during pregnancy relate to better maternal or infant health? The review separates changes in blood measurements from effects on specific health outcomes.

Who was studied?

Five core investigations examined women before or during pregnancy, and their babies. They used different starting concentrations, supplement comparisons and measurement times. The review also considers an infant-growth report that was later corrected.

What did the studies find?

Supplements raised blood status in several trials. Two trials did not show a clear overall benefit in the amount of mineral measured in babies’ bones. One found a possible benefit among winter births in an additional analysis. The other had a small imaging sample. A trial assigning supplements by chance did not show clear prevention of preeclampsia, a pregnancy complication. Associations based on observed blood status did not prove a treatment effect. The growth trial did not detect an infant-growth benefit.

What are the limits?

Not finding a clear difference does not prove treatments have identical effects. Missing measurements and selected groups limit how widely the findings apply. A recent diabetes report was excluded because of conflicting results within its report. These findings do not establish a personal dose, ideal blood target or conclusion about every pregnancy outcome.

Read the full article below ↓

Giving vitamin D during pregnancy can raise a blood measurement without proving an improvement in maternal or infant health. The evidence also differs by outcome: a bone scan, preeclampsia and infant growth are separate questions. This Summary explains the main findings and uncertainties. The detailed assessment is in Vitamin D in Pregnancy: Maternal and Fetal Outcomes: Full Evidence Review.

What was studied?

The review examines five core investigations, plus an infant-growth finding reported in a paper that was later corrected. It also explains why a recent gestational-diabetes report was excluded after assessment. The studies used different populations, starting concentrations, treatment comparisons and times during pregnancy.

The usual status marker is 25-hydroxyvitamin D. It is different from vitamin D3 in a supplement and from the active hormone. Vitamin D Testing: 25-OH-D vs 1,25-OH₂-D explains these substances. Vitamin D Status vs Vitamin D Effect explains why changing a status measurement does not automatically establish a health benefit.

Did supplementation improve newborn bone measurements?

The UK MAVIDOS trial did not demonstrate an overall improvement in its main newborn bone-mineral-content measurement. A secondary analysis suggested a benefit among winter births. That finding deserves attention, but it came from one of several subgroup comparisons and does not replace the overall result. Women with markedly low screening concentrations were excluded, so the trial cannot settle every deficient-pregnancy question.

The Lebanese preg-D trial compared two active supplement regimens. Higher exposure improved maternal and cord blood measurements. It did not demonstrate a clear newborn bone-mineral-content benefit in the small group with usable scans. Many randomized participants lacked complete measurements. The result therefore does not prove that the regimens were equivalent.

Neither trial established fewer fractures. Bone Mineralisation, Turnover and Fractures Measure Different Outcomes explains why bone mineral measurements, bone turnover and fractures are different outcomes.

Did supplementation prevent preeclampsia?

Preeclampsia is a pregnancy complication. In the assessed VDAART comparison, there were 33 cases in the higher-exposure group and 34 in the comparison group, with 408 pregnancies in each. The randomized result did not demonstrate prevention, but its uncertainty also means it did not prove that every possible effect was absent.

Women who achieved higher vitamin D status had lower preeclampsia odds in a separate analysis. However, they were grouped by a later blood result, not simply by their randomized assignment. Other differences between them could affect the association. It cannot establish a personal preventive target.

The EAGeR analysis examined status before conception and early in pregnancy. Vitamin D was not randomized; the original trial concerned aspirin. An association with later preeclampsia became weaker after adjustment for body mass index, a measure relating weight to height. This does not prove that body size fully explains the association or that vitamin D treatment would change the risk. A blood concentration identified during an additional statistical analysis does not establish a treatment target.

What about blood status and infant growth?

The Hollis trial showed that vitamin D3 exposure changed the usual status marker. It did not demonstrate significant differences in how far the pregnancy had progressed at birth, birthweight or the need for more specialized care for newborn babies. Its main purpose was biochemical, and incomplete follow-up limits broader conclusions. Research exposure and monitored safety findings are not a personal supplementation plan.

The Bangladesh MDIG trial did not detect an infant-growth benefit in its principal growth report. A later correction changed numerical material while leaving the stated conclusion unchanged. This review uses only that finding without repeating unverified older numerical estimates. Infant growth is different from the newborn bone measurements in the other trials.

Why was the diabetes report excluded?

A recent report in women who already had gestational diabetes contained important conflicts in its numerical and statistical reporting. After examining the full report and supplement, the review excluded it from reliable benefit estimates. That does not mean vitamin D has been proved helpful or ineffective for diabetes. It means this report cannot reliably settle the question.

What does this mean?

The studies demonstrate biochemical responses more clearly than they establish broad clinical benefits. Some findings remain promising, some comparisons did not detect benefit, and some estimates are too uncertain for a firm conclusion. The evidence does not justify one universal claim about every pregnancy outcome or every population. It also does not establish a personal dose or ideal blood target.

Sources and access

This Summary uses the Full Evidence Review’s assessed studies and exclusions. The detailed review provides publication links, missing-material limits, correction information and the distinction between randomized and observational results. No additional studies are introduced.

Maternal gestational vitamin D supplementation and offspring bone health (MAVIDOS): a multicentre, double-blind, randomised placebo-controlled trial. Cooper C et al. Lancet Diabetes & Endocrinology. 2016;4:393 to 402.

Maternal and neonatal outcomes of vitamin D supplementation in hypovitaminosis D pregnancy: preg-D randomized trial. Chakhtoura M et al. Journal of Clinical Endocrinology & Metabolism. 2026. Supplement DOI 10.6084/m9.figshare.32314851.v1.

Early pregnancy vitamin D status and risk of preeclampsia. Mirzakhani H et al. Journal of Clinical Investigation. 2016;126:4702 to 4715.

Preconception vitamin D status and subsequent risk of preeclampsia: A secondary cohort analysis from the EAGeR trial. Alkhalaf ZM et al. Pregnancy Hypertension. 2026;43:101417.

Vitamin D Supplementation during Pregnancy: Double Blind, Randomized Clinical Trial of Safety and Effectiveness. Hollis BW et al. Journal of Bone and Mineral Research. 2011;26:2341 to 2357. Correction: Erratum: Vitamin D supplementation during pregnancy: Double-blind, randomized clinical trial of safety and effectiveness. 2011.

Vitamin D Supplementation in Pregnancy and Lactation and Infant Growth. Roth DE et al. New England Journal of Medicine. 2018;379:535 to 546. 2021 correction: Vitamin D Supplementation in Pregnancy and Lactation and Infant Growth. Same trial, not a separate study.

The role of vitamin D in pregnancy outcomes in gestational diabetes: a randomized controlled trial. Liu Y et al. Endocrine Connections. 2026;15:e250932. Assessed but excluded from reliable effect estimates for the reasons described above.

Related reading

Original sources

Source

Preconception vitamin D status and subsequent risk of preeclampsia: A secondary cohort analysis from the EAGeR trial

A secondary analysis of the EAGeR Trial (2006 to 2012), which was a multisite, prospective, double-blind, block-randomized, placebo-controlled clinical trial of women with regular menstrual cycles and 1 to 2 prior pregnancy losses.

Publication details

Preconception vitamin D status and subsequent risk of preeclampsia: A secondary cohort analysis from the EAGeR trial. Alkhalaf ZM et al. Pregnancy Hypertension. 2026;43:101417.

Read more →
Source

Vitamin D Supplementation during Pregnancy: Double Blind, Randomized Clinical Trial of Safety and Effectiveness

Published in Hollis BW et al. Journal of Bone and Mineral Research (2011).

Publication details

Vitamin D Supplementation during Pregnancy: Double Blind, Randomized Clinical Trial of Safety and Effectiveness. Hollis BW et al. Journal of Bone and Mineral Research. 2011;26:2341 to 2357. Correction: Erratum: Vitamin D supplementation during pregnancy: Double-blind, randomized clinical trial of safety and effectiveness. 2011.

Read more →
Source

Erratum: Vitamin D supplementation during pregnancy: Double-blind, randomized clinical trial of safety and effectiveness

Vitamin D Supplementation during Pregnancy: Double Blind, Randomized Clinical Trial of Safety and Effectiveness.

Publication details

Vitamin D Supplementation during Pregnancy: Double Blind, Randomized Clinical Trial of Safety and Effectiveness. Hollis BW et al. Journal of Bone and Mineral Research. 2011;26:2341 to 2357. Correction: Erratum: Vitamin D supplementation during pregnancy: Double-blind, randomized clinical trial of safety and effectiveness. 2011.

Read more →
Source

Vitamin D Supplementation in Pregnancy and Lactation and Infant Growth

Published in Roth DE et al. New England Journal of Medicine (2018).

Publication details

Vitamin D Supplementation in Pregnancy and Lactation and Infant Growth. Roth DE et al. New England Journal of Medicine. 2018;379:535 to 546. 2021 correction: Vitamin D Supplementation in Pregnancy and Lactation and Infant Growth. Same trial, not a separate study.

Read more →
Source

Vitamin D Supplementation in Pregnancy and Lactation and Infant Growth

Published in Roth DE et al. New England Journal of Medicine (2018).

Publication details

Vitamin D Supplementation in Pregnancy and Lactation and Infant Growth. Roth DE et al. New England Journal of Medicine. 2018;379:535 to 546. 2021 correction: Vitamin D Supplementation in Pregnancy and Lactation and Infant Growth. Same trial, not a separate study.

Read more →